Daxor Corp (DXR) — SEC Filings
Daxor Corp (DXR) — 10 SEC filings. Latest: 40-17F2 (May 6, 2026). Includes 6 8-K, 2 DEF 14A, 1 40-17F2.
Overview
Daxor Corp (DXR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a N-CEN/A filed on Apr 2, 2026: Daxor Corp. filed an amended N-CEN/A form on April 2, 2026, for the period ending December 31, 2025. This filing includes an independent report on internal controls. The company's mailing and business address is 107 MECO LANE, OAK RIDGE, TN 37830.
Sentiment Summary
Across 10 filings, the sentiment breakdown is: 1 bearish, 9 neutral. The dominant filing sentiment for Daxor Corp is neutral.
Filing Type Overview
Daxor Corp (DXR) has filed 1 40-17F2, 1 N-CEN/A, 6 8-K, 2 DEF 14A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (10)
| Date | Form | Description | Risk |
|---|---|---|---|
| May 6, 2026 | 40-17F2 | 40-17F2 Filing | |
| Apr 2, 2026 | N-CEN/A | Daxor Corp Files Amended N-CEN/A Annual Report | low |
| Aug 7, 2025 | 8-K | Daxor Corp Files 8-K: Other Events & Financials | low |
| Jul 1, 2025 | 8-K | Daxor Corp Files 8-K on Security Holder Vote | low |
| Jun 6, 2025 | DEF 14A | Daxor Sets June 24 Annual Meeting for Director Election, Auditor Ratification | low |
| Jul 18, 2024 | 8-K | Daxor Corp Files 8-K on Security Holder Vote Matters | low |
| Jun 21, 2024 | DEF 14A | Daxor Corp. Sets July 15th Annual Shareholder Meeting | low |
| Jun 5, 2024 | 8-K | Daxor Corp Faces NYSE Delisting Risk | high |
| Mar 25, 2024 | 8-K | Daxor Corp Files 8-K | low |
| Jan 2, 2024 | 8-K | Daxor Corp Relocates Principal Executive Offices to Oak Ridge, TN |
Risk Profile
Risk Assessment: Of DXR's 8 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 7 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Robert J. Michel
Industry Context
Daxor Corp operates within the healthcare technology sector, specifically focusing on diagnostic instrumentation. The industry is characterized by ongoing innovation in medical devices, stringent regulatory oversight from bodies like the FDA, and a competitive landscape with both established players and emerging companies. Trends include the increasing demand for point-of-care diagnostics and the integration of AI in medical devices.
Top Tags
corporate-governance (3) · shareholder-vote (2) · sec-filing (2) · annual-report (1) · internal-controls (1) · registered-investment-company (1) · 8-K (1) · financial-statements (1) · other-events (1) · Proxy Statement (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Period of Report | 2025-12-31 | Indicates the end of the fiscal year for which the report is filed. |
| Filing Date | 2026-04-02 | The date the amended N-CEN/A form was accepted by the SEC. |
| Commission File Number | 811-22684 | Identifies Daxor Corporation's SEC filing history. |
| IRS Employer Identification No. | 13-2682108 | Tax identification number for Daxor Corporation. |
| SEC File Number | 811-22684 | Company's SEC filing identifier |
| Number of directors to be elected | 6 | Each to serve for a term of one year |
| Term length for elected directors | 1 | One year term for each director |
| Votes per share | 1 | Shareholders are entitled to one vote per share |
| Fiscal year for auditor appointment | 2025 | Bush & Associates, CPA appointed for year ending December 31, 2025 |
| Meeting start time | 10:45 AM | Eastern Daylight Time on June 24, 2025 |
| Compliance Deadline | June 28, 2024 | Daxor must submit a plan to regain compliance with NYSE American listing standards by this date. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Daxor Corp (DXR)?
Daxor Corp has 10 recent SEC filings from Jan 2024 to May 2026, including 6 8-K, 2 DEF 14A, 1 40-17F2. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DXR filings?
Across 10 filings, the sentiment breakdown is: 1 bearish, 9 neutral. The dominant sentiment is neutral.
Where can I find Daxor Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Daxor Corp (DXR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Daxor Corp?
Financial highlights for Daxor Corp are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for DXR?
The investment thesis for DXR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Daxor Corp?
Key executives identified across Daxor Corp's filings include Robert J. Michel.
What are the main risk factors for Daxor Corp stock?
Of DXR's 8 assessed filings, 1 were flagged high-risk, 0 medium-risk, and 7 low-risk.
What are recent predictions and forward guidance from Daxor Corp?
Forward guidance and predictions for Daxor Corp are extracted from SEC filings as they are enriched.